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Background: MicroRNAs (miRNAs) are endogenous, small non-coding RNAs that play important roles in multiple
biological processes. MiR-20b has been reported to participate in breast cancer tumorigenic progression, however,
the functional roles are still unclear and under debating. The aim of this study is to explicit the molecular mechanism
of miR-20b underlying breast cancer tumorigenesis.
Results: In the present study, we showed that miR-20b was overexpressed in human breast cancer tissues and cell
lines compared with paired adjacent normal tissues and normal cell lines, respectively. We identified PTEN, a well-known
tumor suppressor, as the functional downstream target of miR-20b. Luciferase assays confirmed that miR-20b could
directly bind to the 3′ untranslated region(UTR) of PTEN and suppress translation. Alteration of miR-20b expression
changed PTEN protein level but not mRNA expression in ZR-75-30 and MCF-7 breast cancer cells, suggesting miR-20b
regulates PTEN gene expression at the posttranscriptional level. Furthermore, upregulation of miR-20b significantly
promoted the proliferation, colony formation and DNA synthesis of ZR-75-30 and MCF-7 breast cancer cells. Conversely,
knockdown of miR-20b expression inhibited the growth of breast cancer cells in vitro and in vivo.
Conclusion: Dysregulation of miR-20b plays critical roles in the breast cancer tumorigenesis, at least in part via targeting
the tumor suppressor PTEN. This microRNA may serve as a potential diagnostic marker and therapeutic target for
breast cancer.
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Breast cancer is the most frequently diagnosed malig-
nancy and the leading cause of cancer death in women
worldwide. Currently, the large number of etiological
factors and the complexity of breast cancer present
challenge for prevention and treatment. Breast cancer
tumorigenesis can be described as a multi-step process
in which a normal cell undergoes malignant transform-
ation to a fully developed tumor through accumulations
of genetic and epigenetic changes [1]. Although alter-
ations in many oncogenic and tumor-suppressive genes
are reportedly implicated in breast cancer, the molecular* Correspondence: bali@xmu.edu.cn; zhangzhiming164@aliyun.com
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tumor cells remains poorly understood.
MicroRNAs (miRNAs) are endogenous, small non-
coding RNAs that regulate gene expression at the post-
transcriptional level [2]. These miRNAs pair with partially
complementary sites in the 3′-untranslated regions (UTRs)
of target mRNAs, leading to translational repression
and/or mRNA degradation. MiRNAs participate in a
wide array of biological processes including develop-
ment and differentiation, cell proliferation, apoptosis,
and metabolism [3,4]. Aberrant miRNA expression has
been frequently observed in various human tumors, indi-
cating an important role of miRNAs in tumorigenesis [5].
Recently, studies of miRNA profiles found several
deregulated miRNAs in breast cancer, including miR-
20b [6,7]. MiR-20b belongs to the miR-106a-363 cluster,
together with miR-17-92 and miR-106b-25 clusters,
form a large family of highly similar miRNAs called thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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bers of the miR-17 family have been reported to accu-
mulate in tumor cells and speculated to have an
oncogenic role [9,10]. The probability of survival was
significantly lower in gastric cancer patients with high ex-
pression levels of miR-20b [11]. MiR-20b was also re-
ported to favor the survival of tumor cells upon the
oxygen supply [12]. These studies suggested that miR-
20b can serve as a potential oncogene. MiR-20b was also
reported to involve regulation of VEGF expression by tar-
geting HIF-1α and STAT3 in MCF-7 breast cancer cells
[13]. A newly-published study has shown that ionizing
radiation, a potent tumor-causing agent, can induce miR-
20b expression in rat mammary gland tissues, and the
transcription factor early growth response-1 involves in
the regulation of miR-20b in the breast cancer cell line
HCC1806 [14].
The present study also showed that miR-20b was up-
regulated in human breast cancer tissues, and a bio-
informatics analysis predicted phosphatase and tensin
homologue (PTEN) to be a potential target of miR-20b.
PTEN gene, a well-known anti-oncogene, encodes a phos-
phatase that converts phosphatidylinositol 3,4,5-trisphos-
phate to phosphatidylinositol 4,5-bisphosphate, thereby
antagonizing the highly oncogenic PI3K/Akt-signaling
pathway [15]. PTEN expression is frequently altered
in a variety of human cancers [16], and subtle changes
in PTEN dose dictate critical outcomes in tumor initi-
ation and progression in vivo [17]. Recent evidence
showed that regulation of the PTEN-PI3K-Akt path-
way by miRNAs plays a crucial role in breast cancer
progression [18], which indicating a novel way to inves-
tigate the tumorigenesis, diagnosis, and therapy of
breast cancer. In this study, we aim to explicit the mo-
lecular mechanism of miR-20b underlying breast cancer
tumorigenesis.
Results
Inverse level of miR-20b and PTEN in breast cancer
We analyzed the expression level of miR-20b in 23
paired clinical breast cancer tissues and the adjacent
normal breast tissues by miRNA qRT-PCR. The average
expression level of miR-20b was significantly increased
in breast cancer tissues compared with paired normal
adjacent tissues (Figure 1A; P < 0.001). We further
assessed the expression level of miR-20b in a panel of
breast cancer cell lines. Compared with the normal
mammary epithelial cell line (MCF-10A), miR-20b ex-
pression level was upregulated in all four examined
breast cancer cell lines (MCF-7, ZR-75-30, T-47D and
SK-BR-3) (Figure 1B). In addition, among the above 23
paired clinical breast cancer tissues and the adjacent
normal breast tissues, we randomly selected 10 patients
for further detecting the PTEN protein expression bywestern blot. The results showed that the PTEN protein
level was downregulated in human breast cancer tissues
compared with in the matching normal breast tissues
(Figure 1C and D). These data indicate that the protein
level of PTEN is negatively correlated with the miR-20b
expression (Additional file 1).
MiR-20b binds directly to the 3′-UTR of PTEN
To explore the molecular mechanism of miR-20b in the
growth of breast cancer cells, we used a bioinformatics
analysis to search for putative protein-coding gene tar-
gets of miR-20b, especially for those that can affect can-
cer cell growth. According to this rationale, PTEN was
selected as the candidate target gene of miR-20b, which
was highly conserved among different species and whose
3′-UTR of mRNA contained a complementary site for
the seed region of miR-20b (Figure 2A). Furthermore,
we performed a luciferase reporter assay to verify that
miR-20b directly targets PTEN. We subcloned PTEN
3′-UTR sequences containing the predicted target site
(wild type, pGL3-wt) of miR-20b or mutated sequences
(mutant type, pGL3-mut) into the pGL3-Control vector,
respectively. The results showed that co-transfection of
miR-20b mimics and pGL3-wt significantly decreased
the luciferase activities in breast cancer cells (ZR-75-
30 and MCF-7) but not that of the mutant reporter
(Figure 2B), indicating that miR-20b binds directly to the
3′-UTR of PTEN.
MiR-20b downregulates PTEN expression at the
posttranscriptional level
To evaluate the effect of miR-20b on PTEN expression
level, we transfected the breast cancer cell lines ZR-75-
30 and MCF-7 with miR-20b mimics or inhibitor. Com-
pared with miR-20b mimic negative control (miR-NC),
transfection with 50 nM of miR-20b mimics in ZR-75-30
and MCF-7 cells led to more than 1000-fold increase in
miR-20b expression as detected by quantitative real-time
PCR (Figure 3A). In contrast, ZR-75-30 and MCF-7 cells
transfected with 100 nM of miR-20b inhibitor dramatic-
ally decreased miR-20b expression level as compared
with that of negative control (inhibitor-NC) transfected
cells (Figure 3B). After transfecting with miR-20b mimics
or inhibitor, no significant difference in PTEN mRNA level
was observed in the both breast cancer cells (Figure 3C
and D). However, miR-20b could significantly downregu-
late PTEN protein level in ZR-75-30 and MCF-7 breast
cancer cells (Figure 3E and F). These data suggest that
miR-20b can downregulate PTEN gene expression at the
posttranscriptional level.
MiR-20b enhances breast cancer cell proliferation
To investigate the effects of miR-20b on breast cancer
tumorigenesis, we first assessed the effects of its expression
Figure 1 Expression of miR-20b is associated with PTEN level. (A) qRT-PCR analysis of miR-20b expression in 23 paired breast tumor
tissues (tumor) and their adjacent normal tissues (normal). ***, P < 0.001. (B) The expression of miR-20b was examined in nontumorigenic
breast epithelial cells (MCF-10A) and breast cancer cell lines, including MCF-7, ZR-75-30, T-47D and SK-BR-3. The miR-20b expression was
normalized by U6 expression. ***, P < 0.001 compared with MCF-10A. (C) Western blot analysis of PTEN protein expression between the
breast tumor and normal tissues. N, normal breast tissue; T, breast tumor tissues. (D) Quantitative analysis of PTEN protein expression. PTEN
expression was normalized by β-actin.
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miR-20b mimics into breast cancer cells ZR-75-30 and
MCF-7, which showed that overexpression of miR-20b
significantly increased the cell viabilities of both breast
cancer cells at 48 h after transfection in comparison
with that of negative control (miR-NC) transfected cells
(P < 0.05) (Figure 4A). Whereas miR-20b inhibition dra-
matically restrained the cell viabilities of ZR-75-30 and
MCF-7 at 48 h after transfection as compared with that of
negative control (inhibitor-NC) transfected cells (P < 0.05)
(Figure 4A). Furthermore, upregulation of miR-20b in
ZR-75-30 and MCF-7 breast cancer cells significantly
enhanced their growth ability, as indicated by the in-
crease in colony numbers (P < 0.05) (Figure 4B). In
addition, to analyze the cell cycle distribution, DNA
content was determined by flow cytometry using PI
staining. We found that the G0/G1 phase was increased
in miR-20b inhibitor-transfected MCF-7 breast cells
compared with control cells. The proportion of cells cor-
responding to the proportion of cells in the S and G2/M
phase was lower in miR-20b inhibitor-transfected MCF-7
cells than that in control cells. It seems that knock-
down of miR-20b expression resulted in cells that
were blocked in G0/G1 phase and could not enter into
S phase for DNA synthesis. Further analysis revealedthat knockdown of miR-20b significantly decreased the
proliferation index of MCF-7 cells (Additional file 2).
MiR-20b promotes DNA synthesis of breast cancer cells
To further investigate the ability of miR-20b to pro-
mote cell proliferation, the 5-ethynyl-2′-deoxyuridine
(EdU) incorporation assays were performed. The re-
sults showed that miR-20b overexpression enhanced
DNA synthesis in both ZR-75-30 and MCF-7 breast
cancer cells. The percentage of miR-20b mimics trans-
fected ZR-75-30 cells (33.62% ± 2.14%) and of miR-
20b mimics transfected MCF-7 cells (29.08% ± 3.61%)
showed newly synthesized DNA by the EdU incorpor-
ation assays were significantly higher than that of ZR-
75-30 control cells (25.61% ± 3.61%) and MCF-7 control
cells (19.82% ± 4.41%) (Figure 5; P < 0.05). Meanwhile,
miR-20b inhibitor suppressed DNA synthesis in both
ZR-75-30 and MCF-7 breast cancer cells. The per-
centage of EdU positive cells in miR-20b inhibitor
transfected ZR-75-30 cells (35.51% ± 2.24%) and MCF-
7 cells (25.79% ± 3.95%) were significantly decreased
as compared with that of in negative control trans-
fected ZR-75-30 cells (40.47% ± 4.73%) and MCF-7cells
(30.88% ± 3.52%) (Figure 6; P < 0.05). Collectively, these
results support the role of miR-20b in the promotion of
Figure 2 MiR-20b directly targets the 3′-UTR of PTEN. (A) Sequence alignment of the miR-20b base-paring site in the 3′-UTR of PTEN mRNA.
The region complementary to the seven nucleotides of miR-20b is highly conserved among human, chimpanzee, mouse, rat, and xenopus. The
“seed” sequence of miR-20b that is complementary to PTEN is shown in the box. The mutant sequence (PTEN-3′-UTR-mut) is identical to the
wild-type sequence (PTEN-3′-UTR-wt) except the mutated nucleotides are shown in italics. (B) Luciferase assays in ZR-75-30 and MCF-7 breast
cancer cells. Cells were cotransfected with wt/mut 3′-UTR with miR-20b mimics or negative control as indicated. Forty-eight hours after transfection,
luciferase activity was detected using Dual-Luciferase Reporter Assay System according to the manufacturer’s instruction. Error bars represent mean ± SD
from three independent experiments. *, P< 0.05 when compared with corresponding negative control.
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has an oncogene function.
MiR-20b knockdown suppresses tumor growth in vivo
In the present study, we found that miR-20b was over-
expressed in human breast cancer cells. To further in-
vestigate whether the downregulation of miR-20b can
suppress tumorigenicity of breast cancer cells, ZR-75-30
breast cancer cells transfected with antagomir-20b or
negative control (NC) were subcutaneously inoculated
into BALB/c nude mice and their tumorignicity was
investigated. Compared with the NC-transfected group,
cells transfected with antagomir-20b revealed a delayed
tumor formation time and a significant reduction in the
tumor size, indicating a potential tumor suppressive ef-
fect of antagomir-20b in vivo (Figure 7B). The results
also showed that miR-20b expression level was signifi-
cantly decreased in tumor tissues of antagomir-20b
group (Figure 7C). Inversely, the increased level of
PTEN protein expression was detected in tumor tissues
of antagomir-20b group by immunohistochemistry as
compared with the NC group (Figure 7D). These results
indicated that miR-20b knockdown could suppress the
breast tumor growth in vivo.Discussion
MicroRNAs are known to regulate the expression of genes
involved in a wide range of biological processes, such as
tumor development, proliferation, apoptosis and stress
response [3,19]. Considering the function of miRNAs,
their imbalance expectedly contributes to substantial cell
physiological and pathological processes and is ultimately
participated in tumorigenesis and the tumor progression
of multiple human cancers. In this study, we observed that
upregulation of miR-20b in human breast cancer was as-
sociated with PTEN protein expression level. MiR-20b
could downregulate PTEN protein expression by directly
targeting the 3′-UTR of PTEN. Upregulation of miR-20b
significantly promoted ZR-75-30 and MCF-7 breast cancer
cells viability, colony formation, and led to enhancing
DNA synthesis. Conversely, downregulation of miR-20b
could significantly inhibit these processes in ZR-75-30 and
MCF-7 cells. In addition, knockdown of miR-20b expres-
sion could suppress the cell cycle progression in MCF-7
breast cells. Moreover, miR-20b knockdown could sup-
press tumorigenicity of breast cancer cells in vivo. These
results suggest that miR-20b functions as an oncomir by
contributing to breast tumorigenesis partly via regulating
PTEN expression at the posttranscriptional level.
Figure 3 MiR-20b inhibits PTEN protein expression. (A-B) MiR-20b expression was detected by qRT-PCR. ZR-75-30 and MCF-7 breast cancer
cells transfected with miR-20b mimics showed a significant increase in miR-20b expression (A), while the cells transfected with miR-20b inhibitor
resulted in a significant decrease of miR-20b expression (B). (C-D) qRT-PCR analysis of PTEN mRNA expression. ZR-75-30 and MCF-7 breast cancer
cells transfected with miR-20b mimics or inhibitor did not affect PTEN mRNA expression. (E) Representative pictures of PTEN protein expression
detected by western blot. (F) Quantitative analysis showed that PTEN protein expression in breast cancer cells transfected with miR-20b mimics
decreased when compared with the negative control. Error bars represent mean ± SD from three independent experiments. *, P < 0.05; ***, P < 0.001.
NS, no significant differences.
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pathogenesis of breast cancer, the molecular mechanism
has not been clearly elucidated. A study by Li et al. indi-
cated that one of the most important facets underlying
metastatic heterogeneity of breast cancer is the differen-
tial distribution of miR-20a and miR-20b and their regu-
lation of target proteins, such as VEGF-A and HIF-1α
[6]. Cascio et al. reported that miR-20b could regulate
the expression of vascular endothelial growth factor
(VEGF) in MCF-7 breast cancer cells under normoxic
and hypoxia-mimicking conditions, which was mediated
by hypoxia inducible factor 1 (HIF-1) and signal trans-
ducer and activator of transcription 3 (STAT3) [13]. Li
et al. reported that ionizing radiation, a known breast
carcinogen, could trigger the differential expression of
miR-20b in mammary tissues. The zinc finger transcrip-
tion factor early growth response-1 (EGR1) is a crucial
player in the transcriptional control of miR-20b, andmiR-20b may in turn function as an oncogene by con-
tributing to breast tumorigenesis [14]. In this study, we
further investigated the function and possible mecha-
nisms of miR-20b in regulating some biological proper-
ties of breast cancer cells. The results obtained from
gain-of-function and loss-of-function approaches showed
that miR-20b could enhance the cell viability, colony for-
mation and DNA synthesis of breast cancer cells in vitro.
Moreover, in the study of nude mice model, we validated
that knockdown of miR-20b expression level could sup-
press the tumorigenesis of breast cancer cells in vivo.
These findings suggested that deregulation of miR-20b
played an important role in promoting carcinogenesis and
progression of breast cancer.
To explore the molecular mechanism of miR-20b
upon the growth of breast cancer cells, we confirmed
that miR-20b could directly bind to the 3′-UTR of
PTEN and suppress the translation. PTEN is originally
Figure 4 Effects of miR-20b on proliferation of breast cancer cells. (A) ZR-75-30 (left-panel) and MCF-7 (right-panel) breast cancer cells were
transfected with miR-20b mimics and miR-20b inhibitor. MTS assays were used to detect the cell viability after the indicated periods. (B) The colony
formation assays showed that upregulation of miR-20b in ZR-75-30 and MCF-7 breast cancer cells significantly enhanced their growth ability, as
indicated by the increase in colony numbers. Each bar represents the mean of three independent experiments. *, P < 0.05.
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quently loss in various human cancers [15]. It functions
as a negative regulator of the PI3K/Akt pathway via
dephosphorylation of phosphatidylinositol‑3,4,5‑trispho-
sphate (PIP3), ultimately participating in regulation of
the cell cycle, proliferation, apoptosis, migration, inva-
sion and metastasis during cancer progression [20].
Recently, PTEN has been shown to be regulated by
miRNAs in multiple cancers, including glioma [21],
colorectal carcinoma [22], hepatocellular carcinoma [23]
and ovarian cancer [24]. Especially, Wu et al. reported
that miR-32 could enhance the growth, migration, and
invasion in colorectal carcinoma cells by regulating
PTEN expression [22]. Wang et al. found that miR-21
modulated chemosensitivity of breast cancer cells to
doxorubicin by targeting PTEN [25]. Liang and his team
found that miR-19 involved in multidrug resistance
through modulation of PTEN in breast tumor cells [26].
In addition, Ma et al. demonstrated that overexpressed
microRNA-301a in breast cancer promoted tumor me-
tastasis by targeting PTEN and activating Wnt/beta-ca-
tenin signaling [27]. Li et al. reported that miR-20b
downregulated PTEN expression in HCC1806 cells [14].
A newly study also showed that miR-20b, −21, and -130b
were involved in suppression of PTEN expression in
colorectal cancer [28]. In this study we also deter-
mined that miR-20b inhibited PTEN protein expressionby directly binding to the 3′-UTR of PTEN in ZR-75-
30 and MCF-7 breast cancer cells. Interestingly, over-
expression of miR-20b in ZR-75-30 and MCF-7 breast
cancer cells did not significantly change the mRNA expres-
sion of PTEN, indicating that miR-20b regulates PTEN ex-
pression at the posttranscriptional level. Above all, these
studies showed that miR-20b served as an important onco-
mir in promoting multiple cancer cells growth through
regulating tumor suppressor PTEN expression.
Conclusions
The present study uncovered an oncogenic function of
miR-20b that was frequently overexpressed in breast
cancer tissues and cell lines. MiR-20b serves as an onco-
mir that plays an important role in the growth of breast
cancer cells partly by targeting tumor suppressor PTEN
at the posttranscriptional level. Notably, knockdown
of miR-20b expression displays anti-tumor effects both
in vitro and in vivo. Therefore, miR-20b may be a novel
diagnostic marker and potential therapeutic target in breast
cancer.
Materials and methods
Breast cancer tissue specimens
Human breast cancer specimens and matching normal
breast tissue samples were surgically resected from 23
patients who had undergone surgery in the breast surgery
Figure 5 Upregulation of miR-20b promotes breast cancer cell proliferation through enhancing DNA synthesis. ZR-75-30 cells (top-panel)
and MCF-7 cells (below-panel) were transfected with miR-20b mimics or negative control; 48 hours after transfection, EdU labeling assays were
performed. Representative micrographs (200×) and quantification of EdU incorporating-cells after transfection with miR-20b mimics or negative control.
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University (from 2012 to 2013). The average age at time
of diagnosis was 54 years (range: 43–72 years). None of
the patients had received preoperative treatment, such
as radiotherapy or chemotherapy.
This study was approved by the Ethics Committee
of the First Affiliated Hospital of Xiamen University,
Xiamen, Fujian, China. All patients provided written in-
formed consent.
Cell culture and transfection
Human normal mammary epithelial cell line MCF-10A
was cultured in DME/F12 medium (Gibco, USA) con-
taining 5% horse serum, 10 μ g/ml insulin, 20 ng/ml
EGF, 100 ng/ml choleratoxin, 0.5 μg/ml hydrocortisone,
100 IU/ml penicillin and 100 μg/ml streptomycin. Hu-
man breast cancer cell lines MCF-7 and T-47D were
maintained in DMEM medium (Gibco) supplemented
with 10% fetal bovine serum (FBS; Gibco), 100 IU/ml
penicillin and 100 μg/ml streptomycin. Other human
breast cancer cell lines ZR-75-30 and SK-BR-3 werecultured in RPMI-1640 medium (Gibco) supplemented
with 10% FBS, 100 IU/ml penicillin and 100 μg/ml
streptomycin in humidified 5% CO2 at 37°C. MiR-20b
mimics, miR-20b inhibitor, antagomir-20b and their
negative control were synthesized by Ribobio (RiboBio
Co. Ltd., Guangzhou, China) [29].
The miR-20b gain-of-function study was performed
using miR-20b mimics (50 nM) and its negative control
(50 nM) on the breast cancer cell lines. The loss-of-
function study was performed with miR-20b inhibitor
(100 nM) and its negative control (100 nM) on the cell
lines. The cells were transfected using Lipofectamine
RNAiMAX reagent (Invitrogen, USA) in accordance with
the manufacturer’s instructions.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. For mature
miR-20b expression analysis, Bulge-loop™ miRNA qRT-
PCR Primer Sets (one RT primer and a pair of qPCR
primers for each set) specific for miR-20b were designed
Figure 6 Inhibition of miR-20b suppresses the proliferation of breast cancer cells. ZR-75-30 cells (top-panel) and MCF-7 cells (below-panel)
were transfected with miR-20b inhibitor or negative control; 48 hours after transfection, EdU labeling assays were performed. Representative
micrographs (200×) and quantification of EdU incorporating-cells after transfection with miR-20b inhibitor or negative control.
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reverse transcribed using the PrimeScript RT reagent Kit
(Takara, Dalian, China) and quantified by qPCR using the
SYBR Premix Ex Taq (TaKaRa) as described previously
[30]. U6 was used as the internal control. mRNA quan-
tification was similar as miRNA quantification, except
that cDNA was reverse transcribed using oligo(dT)18
primer. All quantitative real-time PCR was performed
on the Light Cycler 480 system (Roche, USA). The




CAACAATATCCACT-3′. The specific gene expression
was calculated by using the comparative 2-△△CT method
with GAPDH as calibrator [31].
Western blot analysis
Total protein from breast cancer tissues, adjacent normal
tissues, and cultured cells were extracted using RIPA buffer(Thermo, USA). Whole-cell lysates (30 ~ 40 μg) were sepa-
rated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), and the proteins were trans-
ferred to polyvinylidene difluoride membranes by electro-
blotting. Non-specific binding was blocked by incubating
the membranes in 5% non-fat milk in TBST (50 mmol/L
Tris–HCl, 150 mmol/L NaCl, 0.1% Tween-20) for 1 h at
room temperature. Membranes were incubated overnight
at 4°C with PTEN antibody (Cell Signaling Technology,
USA) and β-actin antibody (Santa Cruz, USA) both at a
1:1000 dilution. The membranes were subsequently incu-
bated with a horseradish peroxidase-conjugated secondary
antibody (1:10000; Pierce, Rockford, IL, USA) for 1 hour at
room temperature and visualized using enhanced chemilu-
minescence (Pierce) and X-ray film.
Luciferase reporter assays
The putative binding sites of miR-20b in the 3′-UTR
of the human PTEN gene were predicted by combina-
torial utilization of three different algorithms, including
Figure 7 Knockdown of miR-20b inhibits tumorigenicity of breast cancer cells in vivo. (A) Schematic diagram of the experimental process.
(B) Effects of antagomir-20b on tumor formation in nude mouse xenograft model. Female BALB/c nude mice were inoculated with ZR-75-30 cells
transfected with antagomir-20b or negative control (antagomir NC) on the right flank (n = 6 mice/group). Tumor volume (V) was monitored by
measuring the length (L) and width (W) with vernier caliper and calculated with the formula V = (L ×W2) × 0.5. After 24 days, the mice were sacrificed
and the tumor samples were collected (up-panel). The lower panel shows the volume of the tumors. Data are presented as mean ± SD. *, P< 0.05;
**, P < 0.01 when compared with corresponding negative control. (C) qRT-PCR analysis of miR-20b expression in tumor tissues. ***, P < 0.001. (D) PTEN
expression was detected by immunohistochemistry.
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de/). Direct targeting of the PTEN 3′-UTR was determined
by cloning of the 3′-UTR seed regions and mutated seed
regions into separate pGL3 Luciferase Reporter vectors








TC-3′. The reporter vector plasmid was transfected into
breast cancer cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. To correct
for the transfection efficiency, a luciferase reporter vector
(pRL-TK Vector, Promega) without miR-20b target was
transfected in parallel. Renilla and firefly luciferase activities
were measured using the Dual Luciferase Reporter Assay
System (Promega) and luminescence recorded on a SynergyMulti-Mode Plate Reader (Boitek, USA). MiR-20b function
was expressed as a percent reduction in the luciferase activ-
ity of cells transfected with the reporter vector containing
the miR-20b target sequences compared with cells trans-
fected with the vector without the miR-20b target.
Cell viability assays and colony formation assays
For the cell viability assay, 4 × 103 cells per well were
seeded into a 96-well plate in quintuplicate, the cell
growth was measured by CellTiter 96® AQueous One
Solution Cell Proliferation Assay (MTS; Promega, USA)
after the indicated periods. Absorbance was measured at
490 nm using a microplate reader. For colony forma-
tion assays, cells were plated on 6-well (0.5 × 103 cells
per plate) and cultured for 7 days. The colonies were
stained with 1.0% crystal violet solution for 30 min.
Colonies > 50 μ m in diameter were counted.
5-Ethynyl-2′-deoxyuridine (EdU) labeling assays
Cells were transfected with miR-20b mimics or miR-
20b inhibitor in 96-well plates. Forty-eight hours after
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(Cell-LightTM EdU Apollo567 In Vitro Kit, RiboBio) was
added and the cells were cultured for an additional 2 h.
The cells were then fixed in 4% paraformaldehyde at room
temperature for 30 min. After permeabilization with 0.5%
Triton-X, the cells were incubated with 1 ×Apollo reaction
mixture for 30 min. Subsequently, the cells were stained
with Hoechst 33342 for 30 min at room temperature.
Images were taken and analyzed using Nikon Eclipse
50i fluorescent microscope (Tokyo, Japan). EdU posi-
tive cells were calculated with (EdU add-in cells/Hoechst
stained cells) × 100%.Cell cycle analysis
To analyze the cell cycle distribution, DNA content was
determined by flow cytometry using propidium iodide
(PI) staining. Briefly, cells were harvested, washed twice
with PBS and fixed in 75% ethanol (in 0.01 mol/L PBS)
at 4°C for at least 12 h. After being centrifuged, the cells
were incubated in PBS containing 100 μg/mL DNase-
free RNase A at 37°C for 30 min and subsequently
stained with 50 μg/mL PI on ice for 30 min in the dark.
The cells were analyzed by flow cytometry with a Coulter
EPICS XLTM flow cytometer from Beckman Coulter Inc.
(Brea, CA).In vivo tumorigenicity assays
Healthy female BALB/c Nude mice (4 weeks old) were
obtained from the Xiamen University Laboratory Animal
Centre in Xiamen, China. Animals were maintained for
7 days in a conventional animal care unit before the start
of the study. Animal experiments were performed ac-
cording to ethical guidelines of animal experimentation.
ZR-75-30 cells transfected with antagomir-20b or nega-
tive control (3 × 106 in 0.2 ml PBS) were injected sub-
cutaneously into the right flank of each mouse (6 mice/
each group). Tumor volume (V) was monitored by meas-
uring the length (L) and width (W) with vernier caliper
and calculated with the formula V = (L ×W2) × 0.5. After
24 days, the mice were sacrificed and the tumor samples
were processed for qRT-PCR and immunohistochemistry
examination.Statistical analysis
Data were expressed as the mean ± standard deviation
(SD), and statistical analysis was performed using SPSS
software (version 16.0, Chicago, USA). After testing the
data for normal distribution and equal variance, differ-
ences between two groups were analyzed by the un-
paired Student’s t-test, and differences between multiple
groups were analyzed by ANOVA. P < 0.05 was consid-
ered statistically significant.Additional files
Additional file 1: Figure S1. PTEN protein expression is negatively
correlated with miR-20b expression. Statistical and correlation analyses of
PTEN protein level and miR-20b expression in ten freshly prepared normal
human breast tissues and ten human breast cancer tissues.
Additional file 2: Table S1. Effect of miR-20b on cell cycle in MCF-7 cells.
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